Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap
Deal Expands Existing Cardiovascular Portfolio
Executive Summary
The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028.
You may also be interested in...
BMS Broadens Market, De-Risks Long-Term Revenue Potential For Reblozyl
As a first-line treatment for anemia in patients with myelodysplastic syndromes, Reblozyl is approved for indications that will account for 75%-80% of the $4bn-plus in sales Bristol has forecast by 2029.
As Merck Diversifies Beyond Keytruda, It Will Lean On Its Oncology Leadership Position
Merck Research Laboratories president Dean Li said there is no ideal product mix for the company, but noted cancer drugs will remain a priority given the groundwork Keytruda laid for Merck in oncology.
BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome
The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.